Paysign, Inc. (PAYS) - Q2 2025 10-Q Summary
Business Context and Reporting Period
Paysign, Inc. is a vertically integrated provider of prepaid card products, pharma patient affordability offerings, and digital banking services. This summary covers the quarterly period ended June 30, 2025. The company operates as a single reporting segment and is classified as a non-accelerated filer and smaller reporting company.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) |
|---|---|---|
| Total Revenues | $19.08 million | $37.68 million |
| Gross Profit | $11.76 million | $23.45 million |
| Gross Margin | 61.6% | 62.2% |
| Net Income | $1.39 million | $3.97 million |
| Diluted EPS | $0.02 | $0.07 |
| Operating Cash Flow (YTD) | $(2.39) million (Used) | |
| Cash & Restricted Cash | $113.91 million (as of June 30, 2025) | |
| Total Liabilities | $151.69 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 33.1% in Q2 2025 and 36.9% YTD compared to 2024. This was driven by a 189.9% increase in Pharma industry revenue (Q2) and 223.3% YTD, offset by a 4.7% decline in Plasma industry revenue due to normalized inventory levels.
- Profitability: Net income doubled in Q2 2025 ($1.39M vs. $0.70M) and increased nearly 3x YTD ($3.97M vs. $1.01M). Operating income improved significantly from $125k in Q2 2024 to $1.44M in Q2 2025.
- Acquisition Impact: On March 19, 2025, Paysign acquired Gamma Innovation LLC for a preliminary consideration of $15.56 million. This added $4.49 million in goodwill and $11.07 million in identifiable intangible assets, increasing amortization expenses.
- Cash Flow: Operating cash flow turned negative YTD 2025 ($(2.39)M) compared to positive $28.8M in YTD 2024. This shift is attributed to timing differences in pass-through payments for pharma programs and growth in accounts receivable.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes available cash of $11.75 million (excluding restricted cash) and forecasted revenues will sustain operations for the next 24 months.
- Strategic Focus: Continued investment in technology, cybersecurity, and sales/marketing. The company is leveraging the Gamma acquisition to expand donor engagement solutions in the plasma market.
- Legal Contingencies:
- Securities Class Action: Settled in April 2024 for $3.75 million, fully covered by D&O insurance.
- Derivative Actions: Four pending stockholder derivative actions are in settlement negotiations. A motion for preliminary approval of the settlement was filed in December 2024 and is pending court approval.
- Regulatory: The company is evaluating the impact of the "One Big Beautiful Bill" (OBBB) signed July 4, 2025, on future tax periods.
Investor Verification Checklist
- Pharma Revenue Sustainability: Verify the retention rates of the 33 net pharma programs launched in 2024 and the 21 launched in H1 2025, as this segment drives current growth.
- Plasma Volume Trends: Monitor if the decline in plasma revenue stabilizes following the addition of 123 new centers in Q2 2025.
- Working Capital Management: Assess the timing of receivables vs. payables in the pharma segment, which caused the shift to negative operating cash flow YTD.
- Acquisition Integration: Review the final valuation of the Gamma Innovation acquisition and the realization of projected synergies.
- Legal Settlement Finalization: Confirm the final court approval of the pending stockholder derivative settlement to quantify any potential non-insured liabilities.